跳至主要内容
临床试验/NCT00117780
NCT00117780已完成4 期

Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes

Novo Nordisk A/S4 个研究点 分布在 3 个国家目标入组 520 人开始时间: 2005年6月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
520
试验地点
4
主要终点
Mean HbA1c

研究概览

简要总结

This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight and side effects).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes for more than 1 year
  • Subject treated by any kind of insulin regimen and whatever the number of injections
  • HbA1c = 7.5% and = 10%

排除标准

  • Type 2 diabetes
  • Treatment by oral anti-diabetic drugs
  • Severe medical conditions

结局指标

主要结局

Mean HbA1c

时间窗: after 4 months of insulin detemir treatment

次要结局

  • HbA1c
  • Adverse events
  • Weight
  • Hypoglycaemia
  • Blood glucose
  • Insulin dose requirements during initial 4 months of treatment and during 3 months extension

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验